Needham & Company LLC Reaffirms “Hold” Rating for Inogen (NASDAQ:INGN)

Inogen (NASDAQ:INGN)‘s stock had its “hold” rating reissued by equities researchers at Needham & Company LLC in a report released on Wednesday,Benzinga reports.

Separately, StockNews.com raised Inogen from a “hold” rating to a “buy” rating in a research note on Monday, February 10th.

Inogen Price Performance

INGN stock opened at $7.95 on Wednesday. The company’s 50-day moving average is $10.19 and its 200-day moving average is $10.25. The stock has a market capitalization of $189.35 million, a PE ratio of -3.53 and a beta of 1.02. Inogen has a 1 year low of $5.82 and a 1 year high of $13.33.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its holdings in shares of Inogen by 2.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 896,106 shares of the medical technology company’s stock worth $8,692,000 after acquiring an additional 23,891 shares during the last quarter. Ameriprise Financial Inc. raised its stake in shares of Inogen by 0.6% in the fourth quarter. Ameriprise Financial Inc. now owns 848,980 shares of the medical technology company’s stock worth $7,785,000 after purchasing an additional 5,148 shares during the last quarter. Bridgeway Capital Management LLC lifted its holdings in shares of Inogen by 4.7% in the fourth quarter. Bridgeway Capital Management LLC now owns 631,230 shares of the medical technology company’s stock valued at $5,788,000 after purchasing an additional 28,517 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Inogen by 25.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company’s stock valued at $5,574,000 after purchasing an additional 123,208 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Inogen by 1.1% during the third quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock valued at $5,377,000 after buying an additional 5,921 shares during the last quarter. 89.94% of the stock is currently owned by institutional investors and hedge funds.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.